Targeted Cancer Therapies Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

Description

In the relentless battle against cancer, a new arsenal of weapons is emerging, known as targeted cancer therapies. These precision medicines are transforming the landscape of cancer treatment by taking a highly focused approach to combat this devastating disease. Unlike standard chemotherapy, they zero in on specific molecules responsible for cancer's growth, progression, and spread, sparing normal cells from harm.

Distinguishing Features from Standard Chemotherapy:

1. Pinpoint Precision: Targeted cancer therapies are engineered to seek out and disrupt cancerous cells exclusively, leaving healthy cells untouched.

2. Halting Proliferation: Instead of the widespread destruction of tumor cells characteristic of traditional chemotherapy, targeted therapies put a stop to tumor cell proliferation, arresting the cancer's growth.

Pioneering the Field of Precision Medicine: These therapies represent a cornerstone of precision medicine, a groundbreaking approach that harnesses molecular diagnostic techniques for cancer prevention, diagnosis, and treatment. Precision medicine's potential to usher in a new era of healthcare is increasingly capturing the attention of the anti-cancer drug development industry.

The Expanding Targeted Cancer Therapies Market: The market for targeted cancer therapies encompasses a range of drugs designed as precision medicines for addressing both malignant and benign tumors. Many of these drugs have already received the coveted FDA approval to treat various forms of cancer and are readily available to patients. Meanwhile, numerous others are currently undergoing rigorous clinical trials, with many more in the preclinical testing phase.

Driving Forces for Market Growth:

1. Escalating Cancer Incidence: The rising prevalence of various cancer types, including lung, breast, colorectal, prostate, lymphoma, leukemia, melanoma, and more, is fueling the demand for targeted cancer therapies.

2. Awareness and Diagnostic Advancements: The growing recognition of molecular diagnostic techniques, such as liquid biopsy, for cancer detection, is expected to propel the market forward.

3. Healthcare Investment: Increased healthcare expenditure and expanding insurance coverage are bolstering the revenue potential of the targeted cancer therapies market.

4. Innovation in Drug Development: The continuous pipeline of new targeted anti-cancer drugs is a driving force behind market expansion.

Challenges and Hurdles:

1. Cost Constraints: The elevated pricing of targeted cancer drugs, coupled with the expenses associated with molecular diagnostic tests for cancer detection, may pose challenges to market growth.

Targeted cancer therapies represent a beacon of hope in the ongoing fight against cancer, offering the promise of improved outcomes with fewer side effects. As research and development continue to advance, these precision medicines are poised to play a pivotal role in reshaping the future of cancer treatment.

Market Segmentation

By Therapy Type

Hormone Therapies
Signal Transduction Inhibitors
Gene Expression Modulators
Apoptosis Inducers
Angiogenesis Inhibitors
Immunotherapies
Monoclonal Antibodies

By Disease Indication

Gastrointestinal
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
Melanoma
Prostate Cancer
Others

By End User

Hospitals
Cancer and Radiation Therapy Centers
Clinics

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Targeted Cancer Therapies Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Targeted Cancer Therapies Market Outlook, 2018 - 2031

3.1. Global Targeted Cancer Therapies Market Outlook, by Therapy Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Hormone Therapies
  - 3.1.1.2. Signal Transduction Inhibitors
  - 3.1.1.3. Gene Expression Modulators
  - 3.1.1.4. Apoptosis Inducers
  - 3.1.1.5. Angiogenesis Inhibitors
  - 3.1.1.6. Immunotherapies
  - 3.1.1.7. Monoclonal Antibodies
3.2. Global Targeted Cancer Therapies Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Gastrointestinal
  - 3.2.1.2. Lung Cancer
  - 3.2.1.3. Breast Cancer
  - 3.2.1.4. Colorectal Cancer
  - 3.2.1.5. Leukemia
  - 3.2.1.6. Lymphoma
  - 3.2.1.7. Melanoma
  - 3.2.1.8. Prostate Cancer
  - 3.2.1.9. Others
3.3. Global Targeted Cancer Therapies Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospitals
  - 3.3.1.2. Cancer and Radiation Therapy Centers
  - 3.3.1.3. Clinics
3.4. Global Targeted Cancer Therapies Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Targeted Cancer Therapies Market Outlook, 2018 - 2031

4.1. North America Targeted Cancer Therapies Market Outlook, by Therapy Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Hormone Therapies
  - 4.1.1.2. Signal Transduction Inhibitors
  - 4.1.1.3. Gene Expression Modulators
  - 4.1.1.4. Apoptosis Inducers
  - 4.1.1.5. Angiogenesis Inhibitors
  - 4.1.1.6. Immunotherapies
  - 4.1.1.7. Monoclonal Antibodies
4.2. North America Targeted Cancer Therapies Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Gastrointestinal
  - 4.2.1.2. Lung Cancer
  - 4.2.1.3. Breast Cancer
  - 4.2.1.4. Colorectal Cancer
  - 4.2.1.5. Leukemia
  - 4.2.1.6. Lymphoma
  - 4.2.1.7. Melanoma
  - 4.2.1.8. Prostate Cancer
  - 4.2.1.9. Others
4.3. North America Targeted Cancer Therapies Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospitals
  - 4.3.1.2. Cancer and Radiation Therapy Centers
  - 4.3.1.3. Clinics
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Targeted Cancer Therapies Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Targeted Cancer Therapies Market Outlook, 2018 - 2031

5.1. Europe Targeted Cancer Therapies Market Outlook, by Therapy Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Hormone Therapies
  - 5.1.1.2. Signal Transduction Inhibitors
  - 5.1.1.3. Gene Expression Modulators
  - 5.1.1.4. Apoptosis Inducers
  - 5.1.1.5. Angiogenesis Inhibitors
  - 5.1.1.6. Immunotherapies
  - 5.1.1.7. Monoclonal Antibodies
5.2. Europe Targeted Cancer Therapies Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Gastrointestinal
  - 5.2.1.2. Lung Cancer
  - 5.2.1.3. Breast Cancer
  - 5.2.1.4. Colorectal Cancer
  - 5.2.1.5. Leukemia
  - 5.2.1.6. Lymphoma
  - 5.2.1.7. Melanoma
  - 5.2.1.8. Prostate Cancer
  - 5.2.1.9. Others
5.3. Europe Targeted Cancer Therapies Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospitals
  - 5.3.1.2. Cancer and Radiation Therapy Centers
  - 5.3.1.3. Clinics
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Targeted Cancer Therapies Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Targeted Cancer Therapies Market Outlook, 2018 - 2031

6.1. Asia Pacific Targeted Cancer Therapies Market Outlook, by Therapy Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Hormone Therapies
  - 6.1.1.2. Signal Transduction Inhibitors
  - 6.1.1.3. Gene Expression Modulators
  - 6.1.1.4. Apoptosis Inducers
  - 6.1.1.5. Angiogenesis Inhibitors
  - 6.1.1.6. Immunotherapies
  - 6.1.1.7. Monoclonal Antibodies
6.2. Asia Pacific Targeted Cancer Therapies Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Gastrointestinal
  - 6.2.1.2. Lung Cancer
  - 6.2.1.3. Breast Cancer
  - 6.2.1.4. Colorectal Cancer
  - 6.2.1.5. Leukemia
  - 6.2.1.6. Lymphoma
  - 6.2.1.7. Melanoma
  - 6.2.1.8. Prostate Cancer
  - 6.2.1.9. Others
6.3. Asia Pacific Targeted Cancer Therapies Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospitals
  - 6.3.1.2. Cancer and Radiation Therapy Centers
  - 6.3.1.3. Clinics
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Targeted Cancer Therapies Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Targeted Cancer Therapies Market Outlook, 2018 - 2031

7.1. Latin America Targeted Cancer Therapies Market Outlook, by Therapy Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Hormone Therapies
  - 7.1.1.2. Signal Transduction Inhibitors
  - 7.1.1.3. Gene Expression Modulators
  - 7.1.1.4. Apoptosis Inducers
  - 7.1.1.5. Angiogenesis Inhibitors
  - 7.1.1.6. Immunotherapies
  - 7.1.1.7. Monoclonal Antibodies
7.2. Latin America Targeted Cancer Therapies Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
7.3. Latin America Targeted Cancer Therapies Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospitals
  - 7.3.1.2. Cancer and Radiation Therapy Centers
  - 7.3.1.3. Clinics
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Targeted Cancer Therapies Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Targeted Cancer Therapies Market Outlook, 2018 - 2031

8.1. Middle East & Africa Targeted Cancer Therapies Market Outlook, by Therapy Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Hormone Therapies
  - 8.1.1.2. Signal Transduction Inhibitors
  - 8.1.1.3. Gene Expression Modulators
  - 8.1.1.4. Apoptosis Inducers
  - 8.1.1.5. Angiogenesis Inhibitors
  - 8.1.1.6. Immunotherapies
  - 8.1.1.7. Monoclonal Antibodies
8.2. Middle East & Africa Targeted Cancer Therapies Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Gastrointestinal
  - 8.2.1.2. Lung Cancer
  - 8.2.1.3. Breast Cancer
  - 8.2.1.4. Colorectal Cancer
  - 8.2.1.5. Leukemia
  - 8.2.1.6. Lymphoma
  - 8.2.1.7. Melanoma
  - 8.2.1.8. Prostate Cancer
  - 8.2.1.9. Others
8.3. Middle East & Africa Targeted Cancer Therapies Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospitals
  - 8.3.1.2. Cancer and Radiation Therapy Centers
  - 8.3.1.3. Clinics
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Targeted Cancer Therapies Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Targeted Cancer Therapies Market by Therapy Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Targeted Cancer Therapies Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Targeted Cancer Therapies Market by End User, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By End User vs by Disease Indication Heat map
9.2. Manufacturer vs by Disease Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Apple
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Samsung
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Amazon Renewed
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Gazelle
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Best Buy
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Decluttr
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Back Market
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Swappa
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Glyde
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. BuyBackWorld
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. GameStop
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Product Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development
- 9.5.12. uSell
  - 9.5.12.1. Company Overview
  - 9.5.12.2. Product Portfolio
  - 9.5.12.3. Financial Overview
  - 9.5.12.4. Business Strategies and Development
- 9.5.13. eBay
  - 9.5.13.1. Company Overview
  - 9.5.13.2. Product Portfolio
  - 9.5.13.3. Financial Overview
  - 9.5.13.4. Business Strategies and Development
- 9.5.14. GreenBuyback
  - 9.5.14.1. Company Overview
  - 9.5.14.2. Product Portfolio
  - 9.5.14.3. Financial Overview
  - 9.5.14.4. Business Strategies and Development
- 9.5.15. Quick Mobile Fix
  - 9.5.15.1. Company Overview
  - 9.5.15.2. Product Portfolio
  - 9.5.15.3. Financial Overview
  - 9.5.15.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations